GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Laekna Inc (HKSE:02105) » Definitions » Debt-to-Asset

Laekna (HKSE:02105) Debt-to-Asset : 0.11 (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Laekna Debt-to-Asset?

Laekna's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was HK$107.89 Mil. Laekna's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was HK$3.49 Mil. Laekna's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was HK$1,025.01 Mil. Laekna's debt to asset for the quarter that ended in Dec. 2024 was 0.11.

Laekna Debt-to-Asset Historical Data

The historical data trend for Laekna's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laekna Debt-to-Asset Chart

Laekna Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Debt-to-Asset
0.06 0.06 0.06 0.11

Laekna Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Debt-to-Asset Get a 7-Day Free Trial 0.06 0.05 0.06 0.08 0.11

Competitive Comparison of Laekna's Debt-to-Asset

For the Biotechnology subindustry, Laekna's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Laekna's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Laekna's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Laekna's Debt-to-Asset falls into.


;
;

Laekna Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Laekna's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(107.894 + 3.493) / 1025.005
=0.11

Laekna's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(107.894 + 3.493) / 1025.005
=0.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Laekna  (HKSE:02105) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Laekna Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Laekna's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Laekna Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Laekna Inc (HKSE:02105) » Definitions » Debt-to-Asset
Comparable Companies
HKSE:06955 HKSE:01672 HKSE:02256 HKSE:02480 HKSE:02315 HKSE:09966 HKSE:02142 HKSE:01477 HKSE:06660 HKSE:02157 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
4U4:Germany
Address
No. 3-2-467, 5 Xingbin Road (Lin Li Center), Sino-Italy Ningbo Ecological Park, Zhejiang Province, Yuyao, CHN, 201203
Website
https://www.laekna.com
Laekna Inc is a science-driven, clinical-stage biotechnology company. The company has established a comprehensive R&D infrastructure to accelerate the development of molecules from discovery to registrational trials. It has initiated one clinical trial and another five clinical trials for its Core Products LAE002 and LAE001. Among these six clinical trials, three multi-regional clinical trials (MRCTs) are designed to address medical needs in the standard of care (SOC)-resistant cancers. Laekna has two Core Products and 14 other pipeline product candidates. Core Product LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer and PD-1/PD-L1 drug-resistant solid tumors.
Executives
Orbimed Advisors Iii Limited 2102 Investment manager
Orbimed Asia Gp Iii, L.p. 2102 Investment manager
Orbimed Asia Partners Iii, L.p. 2102 Investment manager
Zhong Yi Ning Bo Sheng Tai Yuan Kong Gu Ji Tuan You Xian Gong Si 2201 Interest of corporation controlled by you
Guo Tou Zhao Shang Tou Zi Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Xian Jin Zhi Zao Chan Ye Tou Zi Ji Jin Er Qi You Xian He Huo 2101 Beneficial owner
Yu Yao Yang Ming Gu Quan Tou Zi Ji Jin You Xian Gong Si 2101 Beneficial owner
Laekna Wonderland Limited 2101 Beneficial owner
Lu Chris Xiangyang 2501 Other
Shang Hai Jin Pu Yi Liao Jian Kang Gu Quan Tou Zi Ji Jin Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Shang Hai Jin Pu Yi Liao Jian Kang Gu Quan Tou Zi He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Gp Healthcare Capital, Inc. 2101 Beneficial owner
Liu Zeng 2201 Interest of corporation controlled by you
Ealex Llc 2101 Beneficial owner
Futu Trustee Limited 2301 Trustee

Laekna Headlines

No Headlines